Treatment options and considerations for hypertensive patients to prevent dementia

ABSTRACT Introduction: Dementia is a worldwide health concern, which leads to loss of autonomy. To date no curative treatment is available so focus on modifiable risk factors is of particular interest. Hypertension, particularly midlife high blood pressure, has been associated with an increased risk for cognitive decline and dementia including vascular dementia (VAD) and Alzheimer disease (AD). In this context, antihypertensive treatments might have a preventive effect. The objective of this review was to examine the relationship between antihypertensive therapy and cognitive decline or dementia. Areas covered: A literature search was conducted using PUBMED and the COCHRANE LIBRARY for publications from 1990 onwards mentioning cognitive decline, AD, Vad, mixed dementia, vascular cognitive impairment, hypertension and antihypertensive therapy. Thirty-nine relevant publications including 20 longitudinal studies, 10 randomized-controlled trials and 9 meta-analyses were taken into account. Expert opinion: Most observational studies have suggested a potential preventive effect of antihypertensive therapies on cognitive decline and dementia, particularly calcium channel blockers and renin-angiotensin system blockers. Randomized clinical trials and meta-analyses provided more conflicting results potentially due to methodological issues. In conclusion, antihypertensive therapies may reduce cognitive decline and incidence of dementia. Further randomized clinical trials conducted in populations at higher risk of cognitive decline, with longer periods of follow-up and cognition as the primary outcome are still needed.

[1]  E. O’Brien,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. , 1997, Lancet.

[2]  C. Bulpitt,et al.  Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial , 2008, The Lancet Neurology.

[3]  R. Westendorp,et al.  Use of calcium antagonists and cognitive decline in old age The Leiden 85-plus study , 2008, Neurobiology of Aging.

[4]  M. Cesari,et al.  Angiotensin‐Converting Enzyme Inhibitors and Alzheimer's Disease Progression in Older Adults: Results from the Réseau sur la Maladie d'Alzheimer Français Cohort , 2013, Journal of the American Geriatrics Society.

[5]  L. Ferrucci,et al.  Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. , 2001, American journal of epidemiology.

[6]  J. Goch,et al.  Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study , 2008, Journal of hypertension.

[7]  J. Li,et al.  Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease , 2011, Neurology.

[8]  Philip W. Landfield,et al.  Increase in Single L-Type Calcium Channels in Hippocampal Neurons During Aging , 1996, Science.

[9]  C. Tzourio,et al.  Diuretic antihypertensive drugs and incident dementia risk: a systematic review, meta-analysis and meta-regression of prospective studies , 2016, Journal of hypertension.

[10]  J. Williamson,et al.  Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. , 2009, Archives of internal medicine.

[11]  S. Yusuf,et al.  Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies , 2011, The Lancet Neurology.

[12]  B. Winblad,et al.  The age-dependent relation of blood pressure to cognitive function and dementia , 2005, The Lancet Neurology.

[13]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[14]  Marc Wortmann.  Dementia: a global health priority - highlights from an ADI and World Health Organization report , 2012, Alzheimer's Research & Therapy.

[15]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[16]  O. Hanon,et al.  Antihypertensive Drugs, Prevention of Cognitive Decline and Dementia: A Systematic Review of Observational Studies, Randomized Controlled Trials and Meta-Analyses, with Discussion of Potential Mechanisms , 2015, CNS Drugs.

[17]  Neil M Davies,et al.  Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. , 2011, Journal of Alzheimer's disease : JAD.

[18]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[19]  M. Mattson.  Antigenic changes similar to those seen in neurofibrillary tangles are elicited by glutamate and Ca2+ influx in cultured hippocampal neurons , 1990, Neuron.

[20]  R. Green,et al.  Vascular factors predict rate of progression in Alzheimer disease , 2007, Neurology.

[21]  M. Mattson.  Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. , 1997, Physiological reviews.

[22]  K. Rockwood,et al.  Vascular cognitive impairment: current concepts and clinical developments , 2008, The Lancet Neurology.

[23]  ECiM 6BQ,et al.  Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. , 1992, BMJ.

[24]  B. Costall,et al.  Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition , 1990, Brain Research.

[25]  R. Brookmeyer,et al.  Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging , 2005, Neurobiology of Aging.

[26]  B. Lernfelt,et al.  15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.

[27]  W. Applegate,et al.  Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. , 1994, Archives of internal medicine.

[28]  H. Markus,et al.  Do in vivo Experimental Models Reflect Human Cerebral Small Vessel Disease? a Systematic Review , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  G. Schellenberg,et al.  Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation , 2003, Journal of neurochemistry.

[30]  Z. Wszolek,et al.  VASCULAR RISK FACTORS AND DEMENTIA: HOW TO MOVE FORWARD? , 2009, Neurology.

[31]  M. Albert,et al.  Alzheimer's disease: implications of the updated diagnostic and research criteria. , 2011, The Journal of clinical psychiatry.

[32]  K. Langa,et al.  Mixed dementia: emerging concepts and therapeutic implications. , 2004, JAMA.

[33]  Zheng-rong Wang,et al.  The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta‐analysis of longitudinal studies , 2011, International journal of clinical practice.

[34]  Alessandro Padovani,et al.  Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy , 2005, International journal of geriatric psychiatry.

[35]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[36]  K. Srivastava,et al.  Potassium inhibits free radical formation. , 1994, Hypertension.

[37]  Neil Chapman,et al.  Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. , 2003, Archives of internal medicine.

[38]  R. Hébert,et al.  Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. , 2002, American journal of epidemiology.

[39]  T. Kirkwood,et al.  Antihypertensive drug use and risk of cognitive decline in the very old : an observational study ^ The Newcastle 85 þ Study , 2015 .

[40]  M. Cesari,et al.  Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. , 2005, European heart journal.

[41]  P. Scheltens,et al.  Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer’s Disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[42]  S. Yusuf,et al.  Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo , 2008, The Lancet Neurology.

[43]  P. Stang,et al.  Hypertension and the Rate of Cognitive Decline in Patients With Dementia of the Alzheimer Type , 2004, Alzheimer disease and associated disorders.

[44]  P. Passmore,et al.  Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. , 2009, The Cochrane database of systematic reviews.

[45]  A. Bachoud-Lévi,et al.  Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis , 2013, Journal of hypertension.

[46]  J. Tuomilehto,et al.  Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial , 1998, The Lancet.

[47]  P. Zandi,et al.  Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. , 2006, Archives of neurology.

[48]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[49]  A. Hofman,et al.  Antihypertensive drugs and incidence of dementia: the Rotterdam Study , 2001, Neurobiology of Aging.

[50]  K. Hall,et al.  Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. , 2002, Archives of internal medicine.

[51]  Michael L. Johnson,et al.  Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus , 2012, Alzheimer's & Dementia.

[52]  V. Feigin,et al.  Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? , 2005, Journal of the Neurological Sciences.

[53]  J F Toole,et al.  Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. , 1996, Stroke.

[54]  C. Dufouil,et al.  Cognitive decline in individuals with high blood pressure , 1999, Neurology.

[55]  P. Whitehouse,et al.  Dementia drug development: use of information systems to harmonize global drug development. , 1997, Psychopharmacology bulletin.

[56]  C. You,et al.  No association between hypertension and risk for Alzheimer's disease: a meta-analysis of longitudinal studies. , 2011, Journal of Alzheimer's disease : JAD.

[57]  Florence Pasquier,et al.  Why are stroke patients prone to develop dementia? , 1997, Journal of Neurology.

[58]  D. Selkoe,et al.  Calcium ionophore increases amyloid beta peptide production by cultured cells. , 1994, Biochemistry.

[59]  O. Paulson,et al.  Cerebrovascular consequences of hypertension , 1994, The Lancet.

[60]  V. Hirth,et al.  Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[61]  J. Hardy,et al.  An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease , 1986, Neurobiology of Aging.

[62]  Xin Wang,et al.  The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer’s disease: A meta-analysis , 2016, Journal of Clinical Neuroscience.

[63]  J. Staessen,et al.  Progress in cardiovascular diseases: cognitive function in essential hypertension. , 2006, Progress in cardiovascular diseases.

[64]  Michael J. Berridge,et al.  Calcium Signalling and Alzheimer’s Disease , 2011, Neurochemical Research.

[65]  Jan A Staessen,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.

[66]  J. C. Torre.  Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics , 2004, The Lancet Neurology.

[67]  D. Anderson,et al.  The mechanism of the vasodilator action of potassium. , 1971, The Journal of laboratory and clinical medicine.

[68]  J. Birks,et al.  Nimodipine for primary degenerative, mixed and vascular dementia. , 2002, The Cochrane database of systematic reviews.

[69]  H. Arias,et al.  The role of inflammation in Alzheimer's disease. , 2005, The international journal of biochemistry & cell biology.

[70]  O. Hanon,et al.  Vascular risk factors, cognitve decline, and dementia , 2008, Vascular health and risk management.

[71]  M. Prince,et al.  Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults , 1996, BMJ.

[72]  O. Hanon,et al.  Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors? , 2009, Expert review of neurotherapeutics.

[73]  O. Hanon,et al.  Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors , 2009, Expert review of neurotherapeutics.

[74]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[75]  Frederik Barkhof,et al.  Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease – The LADIS Study , 2009, Cerebrovascular Diseases.

[76]  J. Blass.  Duration of antihypertensive drug use and risk of dementia: A prospective cohort study , 2009 .

[77]  Brian J. Bacskai,et al.  Aβ Plaques Lead to Aberrant Regulation of Calcium Homeostasis In Vivo Resulting in Structural and Functional Disruption of Neuronal Networks , 2008, Neuron.

[78]  V. Haroutunian,et al.  Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons , 2009, Neurology.

[79]  Teng Jiang,et al.  Meta-analysis of modifiable risk factors for Alzheimer's disease , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[80]  Miia Kivipelto,et al.  Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis , 2010, BMJ : British Medical Journal.

[81]  R. Kraftsik,et al.  Cerebral Hypoperfusion Generates Cortical Watershed Microinfarcts in Alzheimer Disease , 2002, Stroke.

[82]  Philip Scheltens,et al.  Midlife Blood Pressure and the Risk of Hippocampal Atrophy: The Honolulu Asia Aging Study , 2004, Hypertension.

[83]  B. Winblad,et al.  Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. , 2003, Archives of neurology.

[84]  L. Launer,et al.  Antihypertensive medication use and risk of cognitive impairment , 2013, Neurology.

[85]  T. Ishimitsu,et al.  High potassium diets reduce vascular and plasma lipid peroxides in stroke-prone spontaneously hypertensive rats. , 1996, Clinical and experimental hypertension.

[86]  D. Leys,et al.  Treatment of vascular risk factors is associated with slower decline in Alzheimer disease , 2009, Neurology.

[87]  Jin-Tai Yu,et al.  Calcium dysregulation in Alzheimer's disease: From mechanisms to therapeutic opportunities , 2009, Progress in Neurobiology.

[88]  Lenore J Launer,et al.  Reducing the Risk of Dementia: Efficacy of Long-Term Treatment of Hypertension , 2006, Stroke.

[89]  G. Ma,et al.  Vascular protective effects of potassium. , 1999, Seminars in nephrology.

[90]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[91]  P. Ghisdal,et al.  Intraneuronal amyloid‐β1‐42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death , 2004, Journal of neurochemistry.

[92]  Kim N. Green,et al.  Linking Calcium to Aβ and Alzheimer's Disease , 2008, Neuron.

[93]  R. Nixon.  The calpains in aging and aging-related diseases , 2003, Ageing Research Reviews.

[94]  J. Bosch,et al.  Use of ramipril in preventing stroke: double blind randomised trial , 2002, BMJ : British Medical Journal.

[95]  Olivier Thibault,et al.  Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store , 2007, Aging cell.

[96]  D. Bennett,et al.  Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. , 2001, Archives of neurology.

[97]  J. C. de la Torre,et al.  For Personal Use. Only Reproduce with Permission the Lancet Publishing Group. Personal View Is Ad Neurodegenerative or Vascular? Is Ad Neurodegenerative? Is Alzheimer's Disease a Neurodegenerative or a Vascular Disorder? Data, Dogma, and Dialectics , 2022 .

[98]  Hong Qing,et al.  Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression , 2006, Proceedings of the National Academy of Sciences.

[99]  O. Hanon,et al.  Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. , 2009, American journal of hypertension.

[100]  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. , 1991, JAMA.

[101]  M. Woodward,et al.  Effects of Blood Pressure Lowering on Cerebral White Matter Hyperintensities in Patients With Stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy , 2005, Circulation.